Transitional cell carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Transitional cell carcinoma
- Therapeutic area
- Oncology
- transitional cell carcinoma
- transitional cell neoplasm
- transitional cell tumor
- transitional cell tumour
- carcinoma of transitional epithelial cell
- carcinoma of urothelial cell
- carcinoma, urothelial, malignant
- transitional carcinoma
- transitional cell carcinoma
- transitional epithelial cell carcinoma
- urothelial cell carcinoma
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0006474
- Parent condition
- MONDO:0004993
Related records
Broader conditions (9)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (36)
- Bartholin gland transitional cell carcinoma
- Bladder carcinoma in situ
- Bladder papillary urothelial carcinoma
- Bladder sarcomatoid transitional cell carcinoma
- Bladder transitional cell carcinoma
- Bladder urachal urothelial carcinoma
- Endometrial transitional cell carcinoma
- Fallopian tube transitional cell carcinoma
- Infiltrating bladder lymphoepithelioma-like carcinoma
- Infiltrating bladder urothelial carcinoma
- Infiltrating bladder urothelial carcinoma sarcomatoid variant
- Infiltrating bladder urothelial carcinoma, clear cell variant
- Infiltrating renal pelvis transitional cell carcinoma
- Infiltrating ureter transitional cell carcinoma
- Kidney pelvis sarcomatoid transitional cell carcinoma
- Lipid-cell variant infiltrating bladder urothelial carcinoma
- Lymphoma-like variant infiltrating bladder urothelial carcinoma
- Microcystic variant infiltrating bladder urothelial carcinoma
- Micropapillary variant infiltrating bladder urothelial carcinoma
- Nested variant infiltrating bladder urothelial carcinoma
Trials (612)
- 18F-LN1 PET/CT in Urothelial Carcinomas
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
- 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma
- A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
- A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
- A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
- A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
- A Multicenter Cancer Biospecimen Collection Study
- A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
- A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Approved drugs (5)
- Atezolizumab
- Enfortumab vedotin
- Nivolumab
- Pembrolizumab
- Vinflunine ditartrate
Drugs in development (17)
- Cabazitaxel Phase 2
- Cisplatin Phase 2
- Dactolisib Phase 2
- Docetaxel Phase 2
- Everolimus Phase 2
- Fluorouracil Phase 2
- Gemcitabine Phase 3
- Ifosfamide Phase 2
- Lycopene Phase 2
- Mitomycin Phase 3
- Oxaliplatin Phase 2
- Paclitaxel Phase 2
- Ramucirumab Phase 2
- Sapanisertib Phase 2
- Tesetaxel Phase 2
- Vinflunine Phase 2
- Vofatamab Phase 1